Effect of Posterior TAP Block on ANI-Guided Remifentanil Consumption in Gynecologic Laparotomy

November 10, 2026 updated by: Sevda Akdeniz,MD, Samsun University

Effect of Preoperative Posterior Transversus Abdominis Plane Block on Intraoperative Remifentanil Consumption Under Analgesia Nociception Index Guidance in Gynecologic Laparotomy: A Prospective, Randomized Controlled Trial

The aim of this study is to evaluate the effect of preoperative posterior transversus abdominis plane (TAP) block on intraoperative remifentanil consumption in patients undergoing gynecological laparotomy under Analgesia Nociception Index (ANI)-guided general anesthesia.

Study Overview

Detailed Description

A standardized anesthesia and analgesia protocol will be applied to all participants undergoing elective gynecological laparotomy. Participants will be randomly divided into two groups: those receiving preoperative ultrasound-guided bilateral posterior transversus abdominis plane (TAP) block and those without block. Intraoperative monitoring will include heart rate, noninvasive mean arterial pressure, oxygen saturation, Analgesia Nociception Index (ANI), and Bispectral Index (BIS). Remifentanil infusion will be adjusted according to ANI values, with a target range of 50-70. Intraoperative remifentanil consumption and postoperative analgesia will be compared between the two groups.

Study Type

Interventional

Enrollment (Estimated)

64

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Samsun, Turkey (Türkiye)
        • Samsun University - Samsun Education and Research Hospital
        • Contact:
        • Contact:
          • Emre C Soydan
          • Phone Number: +905366422896

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Female patients aged 18 to 70 years
  • Scheduled for elective gynecologic laparotomy under general anesthesia
  • ASA physical status I to III
  • Planned perioperative management according to the study protocol
  • Written informed consent obtained

Exclusion Criteria:

  • Refusal to participate
  • Contraindication to posterior transversus abdominis plane block
  • Allergy or hypersensitivity to local anesthetic agents or study medications
  • Coagulopathy or ongoing anticoagulant therapy that precludes regional anesthesia
  • Infection at the planned block site
  • Body mass index greater than 35 kg/m2
  • Chronic opioid use
  • Pregnancy
  • Inability to understand the pain scoring system or use patient-controlled analgesia
  • Conversion to a surgical procedure outside the planned gynecologic laparotomy protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Posterior TAP Block Group

Participants in this group will receive preoperative ultrasound-guided bilateral posterior transversus abdominis plane (TAP) block in addition to standardized general anesthesia. Intraoperative remifentanil infusion will be adjusted according to ANI values, targeting a range of 50-70.

Ultrasound-guided bilateral posterior transversus abdominis plane (TAP) block will be performed preoperatively in patients undergoing gynecological laparotomy.

Bupivacaine 0.25% (2.5 mg/mL) will be administered as a single-shot, ultrasound-guided bilateral posterior transversus abdominis plane (TAP) block before surgery. A total volume of 40 mL (100 mg) will be administered, with 20 mL (50 mg) injected on each side. The intervention will be performed only in the experimental group.

No Intervention: Control Group

Participants in this group will not receive a TAP block. Standardized general anesthesia will be administered, and intraoperative remifentanil infusion will be adjusted according to ANI values, targeting a range of 50-70.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intraoperative Remifentanil Consumption
Time Frame: Intraoperative period

Intraoperative remifentanil consumption will be calculated by dividing the total remifentanil dose by patient body weight and infusion duration, expressed in µg/kg/min.

Intraoperative period

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Numeric rating scale for postoperative pain intensity
Time Frame: up to 24 hours (Will be evaluated at 1, 3, 6, 9, 12, 18, 24 hours)

Evaluated with a Numerical rating scale (NRS) from 0 to 10. (0=no pain; 10=worst imaginable pain)

up to 24 hours (Will be evaluated at 1, 3, 6, 9, 12, 18, 24 hours)
Quality of Recovery - 15 score
Time Frame: Postoperative 24th hour

The impact of surgical and anesthetic interventions on perioperative quality of life and ability to resume routine life activities will be assessed using the Quality of Recovery (QoR) tool. Each question is scored between 0 and 10. The survey result varies between 0-150 points based on the answers given by the patients. Higher scores indicate better recovery.

Postoperative 24th hour
Fentanyl consumption at 30 minutes after arrival in the PACU(post anesthesia care unit)
Time Frame: 30 minutes

Postoperative pain will be assessed using the Numeric Rating Scale (NRS) from 0 to 10. Fentanyl will be administered when the NRS score is ≥4, and the total fentanyl consumption will be recorded in micrograms (µg).

30 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sevda Akdeniz, Samsun University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 20, 2026

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

March 30, 2027

Study Registration Dates

First Submitted

November 2, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe